Cefdinir: an oral cephalosporin for the treatment of respiratory tract infections and skin and skin structure infections
| dc.contributor.author | Sader, Helio S. [UNIFESP] | |
| dc.contributor.author | Jones, Ronald N. | |
| dc.contributor.institution | JMI Labs | |
| dc.contributor.institution | Universidade Federal de São Paulo (UNIFESP) | |
| dc.contributor.institution | Tufts Univ | |
| dc.date.accessioned | 2016-01-24T12:41:53Z | |
| dc.date.available | 2016-01-24T12:41:53Z | |
| dc.date.issued | 2007-02-01 | |
| dc.description.abstract | Cefdinir is an oral third-generation cephalosporin (also known as an advanced-spectrum or generation cephem) with good in vitro activity against the pathogens responsible for community-acquired respiratory tract infections and uncomplicated skin and skin structure infections. the drug distributes very well in respiratory tract tissues and fluids, as well as skin blisters and ear fluids; its pharmacokinetic profile allows once- or twice-daily administration. Oral cefdinir 300 mg twice daily or 600 mg once daily in adults and adolescents, or 14 mg/kg/day in one or two daily doses in pediatric patients, administered for 5 or 10 days, has shown good clinical and bacteriological efficacy, at least equivalent to that of other oral agents in randomized controlled trials conducted in patients with community-acquired pneumonia, acute bacterial exacerbation of chronic bronchitis, sinusitis, acute otitis media, pharyngitis and uncomplicated skin and skin structure infections. Cefdinir is well tolerated and the oral suspension has shown superior taste or palatability over other comparator oral antimicrobial agents. Thus, cefdinir continues to represent an important cephalosporin option for the treatment of adult, adolescent and pediatric patients with mild or moderate respiratory tract or cutaneous infections, especially in areas with elevated rates of beta-lactamase production in Haemophilus influenzae and where resistance to other commonly used agents has emerged (e.g., macrolides, penicillins, tetracyclines, fluoroquinolones and trimethoprim-sulfamethoxazole). | en |
| dc.description.affiliation | JMI Labs, N Liberty Iowa, IA 52317 USA | |
| dc.description.affiliation | Universidade Federal de São Paulo, São Paulo, Brazil | |
| dc.description.affiliation | Tufts Univ, Sch Med, Boston, MA 02111 USA | |
| dc.description.affiliationUnifesp | Universidade Federal de São Paulo, EPM, São Paulo, Brazil | |
| dc.description.source | Web of Science | |
| dc.format.extent | 29-43 | |
| dc.identifier | http://dx.doi.org/10.1586/14787210.5.1.29 | |
| dc.identifier.citation | Expert Review of Anti-infective Therapy. London: Expert Reviews, v. 5, n. 1, p. 29-43, 2007. | |
| dc.identifier.doi | 10.1586/14787210.5.1.29 | |
| dc.identifier.issn | 1478-7210 | |
| dc.identifier.uri | http://repositorio.unifesp.br/handle/11600/29507 | |
| dc.identifier.wos | WOS:000253781000013 | |
| dc.language.iso | eng | |
| dc.publisher | Expert Reviews | |
| dc.relation.ispartof | Expert Review of Anti-infective Therapy | |
| dc.rights | info:eu-repo/semantics/restrictedAccess | |
| dc.subject | acute otitis media | en |
| dc.subject | cefdinir | en |
| dc.subject | group A streptococcal pharyngitis | en |
| dc.subject | Haemophilus influenzae | en |
| dc.subject | oral cephalosporin | en |
| dc.subject | palatability | en |
| dc.subject | respiratory tract infections | en |
| dc.subject | skin and skin structure infections | en |
| dc.subject | Streptococcus pneumoniae | en |
| dc.subject | toleration | en |
| dc.subject | uSSTI | en |
| dc.title | Cefdinir: an oral cephalosporin for the treatment of respiratory tract infections and skin and skin structure infections | en |
| dc.type | info:eu-repo/semantics/article |